Patel G V, Gopal R, Nadkarni J J
Neoplasma. 1984;31(2):197-202.
Immune complexes (IC) were examined in the sera of 100 patients with histologically confirmed non-Hodgkin's lymphoma (NHL) and 80 leukemic patients by the EA-rosette forming cell inhibition assay. Sera from 55 healthy controls were also tested for the presence of IC. Using 9% rosette inhibition as a base-line, IC were observed to be present in 66 out of 100 sera from patients with NHL (66%), 35 out of 80 sera from patients with leukemia (43.7%) and 10 out of 55 control subjects (18%, p less than 0.001). The percentage of positive results was significantly lower in NHL patients with favorable prognosis (45%) than in patients with unfavorable prognosis (80%). IC from the sera of 7 ALL and 6 CML patients were investigated before chemotherapy, in remission and at relapse. The mean inhibitory rate of rosette inhibition was significantly higher in patients during the blastic stage of leukemia than during the complete remission (12.5%), and later it became higher again at the time of relapse. In CML patients, the previously normal serum rosette inhibition activity increased during the blastic crisis. These observations indicate that the follow-up studies of such patients may determine their prognosis accurately.
采用EA玫瑰花结形成细胞抑制试验，检测了100例经组织学确诊的非霍奇金淋巴瘤（NHL）患者和80例白血病患者血清中的免疫复合物（IC）。还检测了55名健康对照者血清中IC的存在情况。以9%的玫瑰花结抑制率作为基线，观察到100例NHL患者中有66例（66%）血清中存在IC，80例白血病患者中有35例（43.7%）血清中存在IC，55名对照者中有10例（18%，p<0.001）血清中存在IC。预后良好的NHL患者阳性结果百分比（45%）显著低于预后不良的患者（80%）。对7例急性淋巴细胞白血病（ALL）和6例慢性粒细胞白血病（CML）患者化疗前、缓解期和复发期血清中的IC进行了研究。白血病患者在急变期玫瑰花结抑制的平均抑制率显著高于完全缓解期（12.5%），随后在复发时再次升高。在CML患者中， blast crisis期间，之前正常的血清玫瑰花结抑制活性增加。这些观察结果表明，对此类患者进行随访研究可能准确地判断其预后。
